Study of cellular oncometabolism via multidimensional protein identification technology

Claire Aukim-Hastie1, Spiros D Garbis2

  • 1Faculty of Health & Medical Sciences, University of Surrey, Guildford, United Kingdom; Faculty of Medicine, Cancer Sciences and CES Units, Institute for Life Sciences, University of Southampton, Southampton, United Kingdom.

Methods in Enzymology
|June 14, 2014
PubMed

Insights

Cellular proteomics, using multidimensional protein identification technology (MuDPIT), offers a robust method for analyzing cancer cell metabolism. This technique enables direct, quantitative proteomic profiling of clinical samples for oncometabolism research.

Area of Science:

  • Biochemistry
  • Oncology
  • Proteomics

Background:

  • Cellular proteomics is a key component of bench-to-bedside translation in clinical applications.
  • Oncogenesis and tumor progression involve significant metabolic alterations, collectively termed oncometabolism.

Purpose of the Study:

  • To describe a multidimensional protein identification technology (MuDPIT)-based strategy for studying the cellular proteome of malignant cells and tissues.
  • To highlight the utility of MuDPIT for analyzing clinical specimens in cancer research.

Main Methods:

  • Utilized a multidimensional protein identification technology (MuDPIT) strategy.
  • Applied the method to analyze the cellular proteome of malignant cells and tissues, including clinical samples.
  • Demonstrated compatibility with reproducible, in-depth analysis of up to a thousand proteins.

Main Results:

  • The MuDPIT strategy proved robust and compatible with the analysis of clinical specimens.
  • The method offers direct, highly sensitive, and reproducible proteomic analysis.
  • MuDPIT provides high resolution, ultra-high mass accuracy, relative quantification, and multiplexing capabilities, limiting costs.

Conclusions:

  • MuDPIT enables direct assessment of the proteomic profile in neoplastic cells and tissues.
  • This technique holds promise as a high-throughput, rapid, quantitative, and cost-effective screening platform for clinical samples in cancer research.